Skip to main content

Advertisement

SpringerLink
Log in

Acute Traveler’s Diarrhea: Initial Treatment

  • Travel Medicine (O Vielemeyer, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

Diarrhea is the most common health issue affecting travelers to destinations across the world. This paper reviews the options for initial treatment of acute traveler’s diarrhea (TD). Its prevention, including but not limited to vaccines and safe travel and eating habits, is an important consideration but is beyond the scope of this paper. Treatment of TD has three arms: volume repletion, antibiotics, and antimotility/antisecretory agents. Patients should be advised to continue a diet that they can tolerate and maintain adequate fluid intake. In most cases, neither oral rehydration therapy nor dietary restrictions are likely to provide significant benefit. As yet, there is no evidence to support probiotic use for treatment of this type of diarrhea. Given that bacteria are the most frequent cause of TD, adult patients with moderate to severe disease should be treated empirically with a short course of antibiotics. In many instances, these will be prescribed pre-travel with instructions for proper usage when typical symptoms occur while abroad. However, such travelers should be advised to see a physician or seek emergency treatment if symptoms are severe or persist beyond 3 days. Antibiotic selection must take into account the epidemiology of resistant enteric pathogens. Fluoroquinolones are usually effective, although resistance of Campylobacter to this class of drugs in South and Southeast Asia warrants azithromycin as first-line empiric therapy in travelers to those regions. One day of therapy is often sufficient but can be extended to 3 days. Rifaximin is an alternative in non-invasive disease only. The antimotility agent loperamide is safe and effective and should be considered as adjunctive therapy in most cases of TD and can similarly be prescribed pre-travel. In non-pregnant adults, bismuth subsalicylate can also provide some symptomatic relief. Where available, racecadotril may be a safe alternative in both adults and children, although never specifically studied in TD. In cases of severe symptoms, or those lasting longer than 3 days, the patient should be evaluated for non-bacterial etiologies as well as possible Clostridium difficile infection. Certain travelers are more vulnerable to severe complications related to TD. Children, particularly infants, may need more aggressive fluid resuscitation with oral rehydration therapy. Several of the antidiarrheal agents must be avoided. Elderly patients and those with impaired cardiovascular reserve or immune-deficient states are more prone to complications as well. Treatment recommendations also differ for pregnant women. We generally advise adult non-pregnant travelers to follow smart eating and drinking practices and to bring a supply of bismuth subsalicylate and loperamide. We also prescribe an empiric antibiotic course (ciprofloxacin or azithromycin for up to 3 days) that is to be used for moderate to severe cases of TD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. Harvey K et al. Surveillance for travel-related disease—GeoSentinel Surveillance System, United States, 1997-2011. Morb Mortal Wkly Rep. 2013;62(3):23.

    Google Scholar 

  2. DuPont, HL. For the record: a history of the definition & management of travelers’ diarrhea. CDC Health Information for International Travel 2014. 2014

  3. von Sonnenburg F et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet. 2000;356(9224):133–4.

    Article  Google Scholar 

  4. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers’ diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg. 2009;80(4):609–14.

    PubMed  Google Scholar 

  5. DuPont HL et al. Rifaximin treatment of pathogen-negative travelers’ diarrhea. J Travel Med. 2007;14(1):16–9.

    Article  PubMed  Google Scholar 

  6. Teague NS et al. Enteric pathogen sampling of tourist restaurants in Bangkok. Thailand J Travel Med. 2010;17(2):118–23.

    Article  Google Scholar 

  7. Jiang ZD et al. Microbial etiology of travelers’ diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol. 2010;48(4):1417–9. Good example of the way technology can enhance our understanding and discovery of potential pathogens in TD.

    Article  PubMed Central  PubMed  Google Scholar 

  8. de la Cabada Bauche J, Dupont HL. New developments in traveler’s diarrhea. Gastroenterol Hepatol (N Y). 2011;7(2):88–95.

    Google Scholar 

  9. Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler’s diarrhea. Clin Infect Dis. 2005;41 Suppl 8:S531–5.

    Article  PubMed  Google Scholar 

  10. Belderok SM et al. Incidence, risk factors and treatment of diarrhoea among Dutch travellers: reasons not to routinely prescribe antibiotics. BMC Infect Dis. 2011;11:295. Article importantly questioning the necessity of prescribing antibiotics for TD in healthy travelers, when the course is most commonly mild and self-limited.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Genton B, D’Acremont V. Evidence of efficacy is not enough to develop recommendations: antibiotics for treatment of traveler’s diarrhea. Clin Infect Dis. 2007;44(11):1520. author reply 1521-2.

    Article  PubMed  Google Scholar 

  12. Mackell S. Traveler’s diarrhea in the pediatric population: etiology and impact. Clin Infect Dis. 2005;41 Suppl 8:S547–52.

    Article  PubMed  Google Scholar 

  13. Nair D. Travelers’ diarrhea: prevention, treatment, and post-trip evaluation. J Fam Pract. 2013;62(7):356–61.

    PubMed  Google Scholar 

  14. Kendall ME et al. Travel-associated enteric infections diagnosed after return to the United States, Foodborne Diseases Active Surveillance Network (FoodNet), 2004-2009. Clin Infect Dis. 2012;54 Suppl 5:S480–7.

    Article  PubMed  Google Scholar 

  15. Norman FF et al. Clostridium difficile-associated diarrhea after antibiotic treatment for traveler’s diarrhea. Clin Infect Dis. 2008;46(7):1060–3.

    Article  PubMed  Google Scholar 

  16. Connor BA. Chronic diarrhea in travelers. Curr Infect Dis Rep. 2013;15(3):203–10.

    Article  PubMed  Google Scholar 

  17. Connor BA, Riddle MS. Post-infectious sequelae of travelers’ diarrhea. J Travel Med. 2013;20(5):303–12.

    Article  PubMed  Google Scholar 

  18. Huang DB, Awasthi M, Le BM, Leve ME, DuPont MW, Dupont HL, et al. The role of diet in the treatment of travelers’ diarrhea: a pilot study. Clin Infect Dis. 2004;39:4.

    Google Scholar 

  19. Atia AN, Buchman AL. Oral rehydration solutions in non-cholera diarrhea: a review. Am J Gastroenterol. 2009;104(10):2596–604. quiz 2605.

    Article  PubMed  Google Scholar 

  20. Caeiro JP et al. Oral rehydration therapy plus loperamide versus loperamide alone in the treatment of traveler’s diarrhea. Clin Infect Dis. 1999;28(6):1286–9.

    Article  CAS  PubMed  Google Scholar 

  21. Marina L, Ritchie TNR. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE. 2012;7(4):11.

    Google Scholar 

  22. Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134(1):e176–91.

    Article  PubMed  Google Scholar 

  23. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008;46 Suppl 2:S96–100. discussion S144-51.

    Article  PubMed  Google Scholar 

  24. Kollaritsch H, Paulke-Korinek M, Wiedermann U. Traveler’s diarrhea. Infect Dis Clin North Am. 2012;26(3):691–706.

    Article  PubMed  Google Scholar 

  25. DuPont HL. Therapy for and prevention of traveler’s diarrhea. Clin Infect Dis. 2007;45 Suppl 1:S78–84. Great overview and interesting historical perspective of TD by one of the pioneers of the field.

    Article  PubMed  Google Scholar 

  26. Ericsson CD. Nonantimicrobial agents in the prevention and treatment of traveler’s diarrhea. Clin Infect Dis. 2005;41 Suppl 8:S557–63.

    Article  CAS  PubMed  Google Scholar 

  27. DuPont HL et al. Five versus three days of ofloxacin therapy for traveler’s diarrhea: a placebo-controlled study. Antimicrob Agents Chemother. 1992;36(1):87–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Adachi JA et al. Empirical antimicrobial therapy for traveler’s diarrhea. Clin Infect Dis. 2000;31(4):1079–83.

    Article  CAS  PubMed  Google Scholar 

  29. Ericsson CD et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers’ diarrhea. A placebo-controlled, randomized trial. Ann Intern Med. 1987;106(2):216–20.

    Article  CAS  PubMed  Google Scholar 

  30. Ericsson CD, DuPont HL, Mathewson JJ. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler’s diarrhea. J Travel Med. 1997;4(1):3–7. One of the original papers demonstrating single day therapy as a treatment option.

    Article  PubMed  Google Scholar 

  31. Fritsche TR, Biedenbach DJ, Jones RN. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler’s diarrhea. Antimicrob Agents Chemother. 2009;53(3):1221–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41 Suppl 2:S144–57.

    Article  CAS  PubMed  Google Scholar 

  33. Solutions THAM. Red Book Online. 2014, Truven Health Analytics.

  34. Tribble DR et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007;44(3):338–46. One of the landmark studies demonstrating the dangers of levofloxacin empiric therapy in areas of resistance, and the feasibility of single dose azithromycin therapy.

    Article  CAS  PubMed  Google Scholar 

  35. Adachi JA et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis. 2003;37(9):1165–71.

    Article  CAS  PubMed  Google Scholar 

  36. Sanders JW et al. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler’s diarrhea in United States military personnel in Turkey. Clin Infect Dis. 2007;45(3):294–301.

    Article  CAS  PubMed  Google Scholar 

  37. In brief: FDA azithromycin warning. Med Lett Drugs Ther. 2013. 55(1413): p. 28.

  38. Pandey P et al. Travelers’ diarrhea in Nepal: an update on the pathogens and antibiotic resistance. J Travel Med. 2011;18(2):102–8.

    Article  PubMed  Google Scholar 

  39. Darkoh C et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 2010;54(9):3618–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. DuPont HL et al. Antibacterial chemoprophylaxis in the prevention of traveler’s diarrhea: evaluation of poorly absorbed oral rifaximin. Clin Infect Dis. 2005;41 Suppl 8:S571–6.

    Article  CAS  PubMed  Google Scholar 

  41. Taylor DN et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother. 2008;52(3):1179–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Steffen R. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol. 2003;98(5):1073–8.

    Article  CAS  PubMed  Google Scholar 

  43. DuPont HL et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33(11):1807–15. Study demonstrating the efficacy of rifaximin versus ciprofloxacin in non-invasive TD.

    Article  CAS  PubMed  Google Scholar 

  44. Dupont HL et al. Treatment of travelers’ diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007;5(4):451–6.

    Article  CAS  PubMed  Google Scholar 

  45. Taylor DN et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am J Trop Med Hyg. 2006;74(6):1060–6.

    CAS  PubMed  Google Scholar 

  46. Gomi H et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob Agents Chemother. 2001;45(1):212–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Goldman RD. Bismuth salicylate for diarrhea in children. Can Fam Physician. 2013;59:2.

    Google Scholar 

  48. R, S. Worldwide efficacy of bismuth subsalicylate in the treatment of travelers’ diarrhea. Rev Infect Dis. 1990;12(1).

  49. Practice parameter: the management of acute gastroenteritis in young children. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Pediatrics, 1996. 97(3): p. 424-35.

  50. Figueroa-Quintanilla D et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N Engl J Med. 1993;328(23):1653–8.

    Article  CAS  PubMed  Google Scholar 

  51. Rao G et al. Bismuth revisited: an effective way to prevent travelers’ diarrhea. J Travel Med. 2004;11(4):239–41.

    Article  PubMed  Google Scholar 

  52. Butler T. Loperamide for the treatment of traveler’s diarrhea: broad or narrow usefulness? Clin Infect Dis. 2008;47(8):1015–6.

    Article  PubMed  Google Scholar 

  53. Placidi E et al. The effects of loperamide, or loperamide plus simethicone, on the distribution of gut water as assessed by MRI in a mannitol model of secretory diarrhoea. Aliment Pharmacol Ther. 2012;36(1):64–73.

    Article  CAS  PubMed  Google Scholar 

  54. Ericsson CD et al. Loperamide plus azithromycin more effectively treats travelers’ diarrhea in Mexico than azithromycin alone. J Travel Med. 2007;14(5):312–9.

    Article  PubMed  Google Scholar 

  55. Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler’s diarrhea: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(8):1007–14. Useful overview and analysis of several studies demonstrating the utility of adjunctive loperamide combined with appropriate antibiotics.

    Article  CAS  PubMed  Google Scholar 

  56. Murphy GS et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med. 1993;118(8):582–6.

    Article  CAS  PubMed  Google Scholar 

  57. Okhuysen PC et al. Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler’s diarrhea: randomized, placebo-controlled trial. Clin Infect Dis. 1995;21(2):341–4.

    Article  CAS  PubMed  Google Scholar 

  58. Crutchley RD, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010;44(5):878–84.

    Article  CAS  PubMed  Google Scholar 

  59. DiCesare D et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol. 2002;97(10):2585–8.

    Article  CAS  PubMed  Google Scholar 

  60. Macarthur RD et al. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14(6):261–73.

    Article  CAS  PubMed  Google Scholar 

  61. Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J Gastroenterol. 2005;11(10):1540–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Salazar-Lindo E et al. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med. 2000;343(7):463–7.

    Article  CAS  PubMed  Google Scholar 

  63. Prado D, G. Global Adult Racecadotril Study. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol. 2002;37(6):656–61.

    Article  CAS  PubMed  Google Scholar 

  64. Gallelli L et al. Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol. 2010;66(2):137–44.

    Article  CAS  PubMed  Google Scholar 

  65. Alam NH et al. Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial. Gut. 2003;52(10):1419–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Nucera E et al. Hypersensitivity to racecadotril: a case report. Eur J Pediatr. 2006;165(6):418–9.

    Article  PubMed  Google Scholar 

  67. Ludan AC. Current management of acute diarrhoeas. Use and abuse of drug therapy. Drugs. 1988;36 Suppl 4:18–25.

    Article  PubMed  Google Scholar 

  68. Boland A, Tunnard GJ, Bazaz R. Over-the-counter kaolin and morphine: two hazards in one. BMJ Case Rep. 2010;2010.

  69. Askling HH, Dalm VA. The medically immunocompromised adult traveler and pre-travel counseling: status quo 2014. Travel Med Infect Dis. 2014;12(3):219–28.

    Article  PubMed  Google Scholar 

  70. Bhadelia N, Klotman M, Caplivski D. The HIV-positive traveler. Am J Med. 2007;120(7):574–80.

    Article  PubMed  Google Scholar 

  71. Smith DS. Travel medicine and vaccines for HIV-infected travelers. Top Antivir Med. 2012;20(3):111–5.

    PubMed  Google Scholar 

  72. Lin KJ et al. Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2013;208(3):221 e1–8.

    Google Scholar 

  73. Yates J. Traveler’s diarrhea. Am Fam Physician. 2005;71(11):2095–100.

    PubMed  Google Scholar 

  74. Bahat Dinur A et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57(7):3307–11.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Ang JY, Mathur A. Traveler’s diarrhea: updates for pediatricians. Pediatr Ann. 2008;37(12):814–20.

    Article  PubMed  Google Scholar 

  76. Granado-Villar D, Cunill-De Sautu B, Granados A. Acute gastroenteritis. Pediatr Rev. 2012;33(11):487–94. quiz 495.

    Article  PubMed  Google Scholar 

  77. Doan S, Steele RW. Advice for families traveling to developing countries with young children. Clin Pediatr (Phila). 2013;52(9):803–11.

    Article  Google Scholar 

  78. Muniyappa P et al. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;49(4):400–4.

    Article  CAS  PubMed  Google Scholar 

  79. Trehan I et al. A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. Am J Gastroenterol. 2009;104(9):2326–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med. 2007;4(3):e98. Important review and meta-analysis of the potential hazards of loperamide in young children.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Cezard JP et al. Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology. 2001;120(4):799–805.

    Article  CAS  PubMed  Google Scholar 

  82. Szajewska H et al. Systematic review: racecadotril in the treatment of acute diarrhoea in children. Aliment Pharmacol Ther. 2007;26(6):807–13.

    Article  CAS  PubMed  Google Scholar 

  83. Guarino A et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132–52.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Kohta Saito has no potential conflicts of interest relevant to this article.

Ole Vielemeyer has no potential conflicts of interest relevant to this article.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Weill Cornell Medical College, 1300 York Ave, #A-421, New York, NY, 10021, USA

    Kohta Saito MD & Ole Vielemeyer MD

Authors
  1. Kohta Saito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ole Vielemeyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kohta Saito MD.

Additional information

This article is part of the Topical Collection on Travel Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saito, K., Vielemeyer, O. Acute Traveler’s Diarrhea: Initial Treatment. Curr Treat Options Infect Dis 7, 63–76 (2015). https://doi.org/10.1007/s40506-015-0039-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-015-0039-3

Keywords

Search

Navigation